Clinical trial registry record

An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 24, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04733534
Last registry update
April 24, 2026
Status
Active Not Recruiting
Phase
Phase 2
Sponsor
St. Jude Children's Research Hospital
Enrollment
110
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
110
Population
ALL · 18 Years
Duration
2022-06-06 to 2027-12-01
Intervention
Dasatinib plus Quercetin; Fisetin
Comparator
Dasatinib plus Quercetin; Fisetin
Outcomes measured
Change in walking speed — Baseline; Change in Walking Speed — Day 30; Change in Walking Speed — Day 60; Change in Walking Speed — Day 150; Senescent cell abundance in blood (p16INK4A) — Baseline; Senescent cell abundance in blood (p16INK4A) — Day 7; Senescent cell abundance in blood (p16INK4A) — Day 30; Senescent cell abundance in blood (p16INK4A) — Day 60; Senescent cell abundance in blood (p16INK4A) — Day 150; Safety of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0 — 150 days; Tolerability of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0 — 15…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Frailty · 100%Title contains controlled term: frailty. Abstract contains controlled term: frailty. Source terminology contains: frailty. Title supplies longevity context: senescence, frailty. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

frailty
Open primary sourceExport JSON